Fiduciary Family Office LLC Has $666,000 Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Fiduciary Family Office LLC reduced its stake in Bristol Myers Squibb by 33.4% during the second quarter, now holding shares valued at $666,000.
• Despite the recent reduction in holdings, institutional investors hold 76.41% of Bristol Myers Squibb's stock, indicating strong interest from financial institutions.
• Bristol Myers Squibb reported earnings of $1.46 per share for the last quarter, exceeding estimates, and plans to pay a quarterly dividend of $0.62 on November 3rd.

Fiduciary Family Office LLC lessened its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 33.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,391 shares of the biopharmaceutical company's stock after selling 7,222 shares during the period. Fiduciary Family Office LLC's holdings in Bristol Myers Squibb were worth $666,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Bristol Myers Squibb in the first quarter worth $31,000. Trifecta Capital Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter worth $25,000. Accent Capital Management LLC acquired a new stake in shares of Bristol Myers Squibb in the first quarter worth $33,000. CBIZ Investment Advisory Services LLC boosted its position in shares of Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 231 shares during the period. Finally, GKV Capital Management Co. Inc. acquired a new stake in shares of Bristol Myers Squibb in the first quarter worth $36,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $43.61 on Tuesday. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The stock's 50-day moving average is $46.03 and its two-hundred day moving average is $47.32. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The firm has a market cap of $88.76 billion, a P/E ratio of 17.58, a price-to-earnings-growth ratio of 2.27 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the company earned $2.07 earnings per share. The business's revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. Bristol Myers Squibb's payout ratio is presently 100.00%.

Analyst Ratings Changes

BMY has been the subject of several recent analyst reports. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets cut Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a research report on Tuesday, August 5th. Daiwa America cut Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Finally, Dbs Bank raised Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $57.23.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.